HSP70与突变型P53在卵巢癌中的表达及临床意义

目的:探讨卵巢上皮癌组织中HSP70与突变型P53(mtP53)的表达情况及其在临床应用E1B-55KD缺陷型腺病毒联合化疗治疗卵巢癌中的指导意义。方法:采用免疫组化方法测定84例卵巢肿瘤(初治癌36例,复发癌23例,良性和交界性肿瘤25例)组织中HSP70与mtP53表达的阳性率。结果:卵巢癌组织中HSP70与mtP53的表达明显高于良性和交界性肿瘤(P<0.05),复发性卵巢癌HSP70与mtP53阳性率明显高于初治卵巢癌,且与卵巢恶性肿瘤的病理分级、进展期密切相关。卵巢癌中HSP70和mtP53共同阳性率为55.93%,复发癌组织中,HSP70和mtP53共同阳性率69.57%,明显高于初治癌(47.22%)。复发癌中铂类耐药型卵巢癌HSP70与mtP53阳性率分别为87.5%、87.5%,均明显高于非耐药组(57.14%、42.86%)。结论:mtP53和HSP70的表达与卵巢癌的进展期及细胞分化程度相关,晚期和低分化的卵巢癌中mtP53与HSP70阳性率明显高于早期和高分化型,提示两者可作为推测卵巢癌预后的指标。铂类耐药型卵巢癌mtP53与HSP70表达率明显高于非耐药型卵巢癌,且复发性卵巢癌mtP53与HSP70共同阳性率明显高于初治卵巢癌,表明mtP53与HSP70的相互作用可能在复发性卵巢癌发展中起作用。而溶瘤性腺病毒应用可能为难治性卵巢癌治疗提供新途径。

Expression and Clinical Significance of MtP53 and HSP70 in Epithelial Ovarian Carcinoma

Objective ： To investigate the expression of HSPT0 and mutant type mtP53 in patients with epithelial o- varian carcinoma and to discuss the clinical significance in use of E1B-deleted adenovirus plus cisplatin-based chemo- therapy on patients with epithelial ovarian carcinoma. Method ： Positive rate of expression of mtP53 and HSP70 were e- valuated for 84 patients with epithelial ovarian cancer （ early cancer 36 cases, recurrent cancer 23 cases, benign and borderline tumors 25 cases） by immunohistochemical method. Result： Positive staining of HSPT0 and mtP53 was signif- icantly higher in malignant tissues than in benign ,borderline malignancy tissues （P 〈 0.05 ） ;HSP70 and mtP53 positive staining were significantly higher in recurrent cancer than in princeps cancer. Furthermore, Positivity was related to the pathological stage and the histological grade. The rate of mtP53 positivity with HSPT0 positivity was 55.9% in ovarian cancer and the rate of mtP53 positivity with HSP70 positivity was 69.57% in recurrent ovarian cancer, which was signif- icantly higher than in princeps cancer （47.22%）. HSPT0 positivity and mtP53 positivity of recurrent cancer were sig- nificantly higher in cisplatin-resist ovarian cancer（87.5% , 87.5% ）than those in non cisplatin-resist cancer （57.14% , 42.86% ）. Conclusion： Expression staining of HSPT0 and mtP53 was correlated with clinical stage and differential grade. Positive rate of HSPT0 and mtP53 in advanced and low differentiation of rovarian carcinoma was significantly higher than that in early and high differentiation phenotype of ovarian carcinoma, which could be reliable indicators of prognosis. The data suggested that HSP70 positivity and mtP53 positivity varian cancer than non cisplatin-resist cancer. There is significant relation were significantly higher in cisplatin-resist obetween the expression of mtP53 and HSP70in epithelial ovarian cancer, especially in recurrent cancer, which indicates that mtP53 and HSP70 may play a important role in the development of recurrent ovarian cancer. Replication-selective adenoviruses are being developed as novel an- ticancer therapeutics to refractory ovarian cancer.